

**DIVI'S LABORATORIES LIMITED**

UN-AUDITED FINANCIAL RESULTS (STANDALONE)  
FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2014


PART-I

(Rs.in Lakhs)

	Particulars	STANDALONE					
		Quarter ended			Nine Months ended		Year Ended
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	<b>Income from operations</b>	<b>78808</b>	82977	68741	<b>225761</b>	176917	250718
	(a) Net Sales/Income from operations (Net of Excise Duty)						
	(b) Other Operating Income	<b>304</b>	337	186	<b>931</b>	420	679
	<b>Total Income from operations (net)</b>	<b>79112</b>	83314	68927	<b>226692</b>	177337	251397
2	<b>Expenses</b>						
	a. Cost of materials consumed	<b>34672</b>	41097	24473	<b>105441</b>	81011	103189
	b. Purchases of stock-in-trade		0	0		0	0
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	<b>(2808)</b>	(6040)	1151	<b>(13626)</b>	(19622)	(11375)
	d. Employee benefits expense	<b>7459</b>	6948	5710	<b>20425</b>	16628	22543
	e. Depreciation and amortization expense	<b>2879</b>	2926	2327	<b>9131</b>	6667	9206
	f. Other Expenses	<b>11080</b>	10629	8814	<b>31546</b>	25417	35154
	<b>Total Expenses</b>	<b>53282</b>	55560	42475	<b>152917</b>	110101	158717
3	<b>Profit from Operations before Other Income, Finance Costs &amp; Exceptional Items (1-2)</b>	<b>25830</b>	27754	26452	<b>73775</b>	67236	92680
4	Other Income	<b>1994</b>	1554	791	<b>4817</b>	9253	8390
5	<b>Profit from ordinary activities before finance costs &amp; exceptional Items (3+4)</b>	<b>27824</b>	29308	27243	<b>78592</b>	76489	101070
6	Finance Costs	<b>48</b>	43	35	<b>127</b>	115	206
7	<b>Profit from ordinary activities after finance costs but before exceptional Items (5-6)</b>	<b>27776</b>	29265	27208	<b>78465</b>	76374	100864
8	Exceptional items	<b>0</b>	0	0	<b>0</b>	0	0
9	<b>Profit from ordinary activities before Tax (7-8)</b>	<b>27776</b>	29265	27208	<b>78465</b>	76374	100864
10	Tax Expense	<b>5718</b>	6301	5306	<b>16650</b>	16508	21692
11	<b>Net Profit from ordinary activities after Tax (9-10)</b>	<b>22058</b>	22964	21902	<b>61815</b>	59866	79172
12	Extra-ordinary items (net of tax expense)	<b>0</b>	0	0	<b>0</b>	0	0
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	<b>22058</b>	22964	21902	<b>61815</b>	59866	79172
14	Share of profit / (loss) of associates	<b>0</b>	0	0	<b>0</b>	0	0
15	Minority Interest	<b>0</b>	0	0	<b>0</b>	0	0



*(Handwritten Signature)*



16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	22058	22964	21902	61815	59866	79172
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						300787
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	16.62	17.30	16.50	46.57	45.10	59.65
	b) Diluted	16.62	17.30	16.50	46.57	45.10	59.65
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	16.62	17.30	16.50	46.57	45.10	59.65
	b) Diluted	16.62	17.30	16.50	46.57	45.10	59.65

PART-II - SELECT INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2014

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	63603674 47.92%	63603674 47.92%	63556194 47.88%	63603674 47.92%	63556194 47.88%	63603674 47.92%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 69130616 100% 52.08%	Nil 69130616 100% 52.08%	Nil 69178096 100% 52.12%	Nil 69130616 100% 52.08%	Nil 69178096 100% 52.12%	Nil 69130616 100% 52.08%

	Particulars	Quarter ended 31-12-2014
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	13
	Disposed off during the quarter	13
	Remaining unresolved at the end of the quarter	Nil

NOTES:

1. The above results for the quarter ended 31<sup>st</sup> December 2014, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 31<sup>st</sup> January, 2015 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.



*(Handwritten signature)*



4. Details of forex gain/loss are given below:

Particulars	Quarter ended			Nine Months ended		Year Ended
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Forex Gain/(Loss)	1116	432	(534)	1683	6842	5042

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. As per the requirements of the Companies Act, 2013 ("the Act"), the company has computed depreciation on the basis of the estimated economic lives or useful lives of fixed assets in the manner prescribed in Schedule II of the Act. Consequently, depreciation for the quarter ended 31<sup>st</sup> December, 2014 is higher by ₹ 60 lakhs and ₹ 765 lakhs for the 9 months ended 31<sup>st</sup> December, 2014. Depreciation of ₹ 1051 lakhs (net of deferred tax) on account of assets whose useful life is already exhausted as on 1<sup>st</sup> April 2014 has been adjusted to Retained Earnings.
6. Figures for the previous year/period have been regrouped or reclassified, wherever necessary.

Place: Hyderabad  
Date: 31-01-2015



for Divi's Laboratories Limited

*Dr. Murali K. Divi*  
Dr. Murali K. Divi  
Chairman & Managing Director

*This is the statement referred to in  
our Limited Review Report dt 31-01-2015*

*N. Acharya*



# **DIVI'S LABORATORIES LIMITED**

**Hyderabad**

**PRESS RELEASE dated 31<sup>st</sup> January, 2015**

## **Divi's Labs earns a PAT of Rs.221 crores in Q3/FY15**

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.221 crores on a total income of Rs.791 crores, on a stand-alone basis, for the quarter ended 31<sup>st</sup> December, 2014. For the corresponding quarter of the last year the company earned a PAT of Rs.219 crores on a total income of Rs. 689 crores.

Forex gain for the current quarter amounted to Rs.11 crores while there was a forex loss of Rs.5 crores during the corresponding quarter last year. The company has capitalized fixed assets aggregating to Rs.143 crores during the current quarter.

The company's operations were affected for a brief period during October, 2014 on account of HUDHUD cyclone at Visakhapatnam.

For the 9-month period ended 31<sup>st</sup> December, 2014, the company earned a total income of Rs.2267 crores as compared to Rs. 1773 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs.785 crores as against a PBT of Rs. 764 crores for the previous period. PAT for the current 9-months is Rs.618 crores as against Rs.599 crores for the previous period.



A handwritten signature in black ink is positioned to the left of a circular stamp. The stamp contains the text "DIVI'S LABORATORIES LTD." around the top inner edge, "Hyderabad-16." in the center, and "D.K. Road, Ameerpet." around the bottom inner edge. There are small star-like symbols on either side of the bottom text.



P.V.R.K. Nageswara Rao & Co.,  
Chartered Accountants

## LIMITED REVIEW REPORT

**TO**  
**THE BOARD OF DIRECTORS OF**  
**DIVI' S LABORATORIES LIMITED**


We have reviewed the accompanying statement of standalone unaudited financial results of **DIVI' S LABORATORIES LIMITED** for the quarter and nine months ended **31<sup>st</sup> December, 2014** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the accounting standards issued under the Companies (Accounting Standard) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014, and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For P.V.R.K. NAGESWARA RAO & Co.,**  
**Chartered Accountants**  
**Firm's Registration Number: 002283S**

  
**N. ANKA RAO**  
**Partner**  
**Membership Number: 23939**



**HYDERABAD**  
**31.01.2015**